Why local production became a national priority

For more than a decade, Algeria has built a clear policy direction: produce locally what can be produced locally, and import only what cannot. That orientation has reshaped the entire pharmaceutical value chain.

The objective is not only economic. It is also about strategic autonomy, securing supply for the national health system, and developing industrial know-how that can support long-term growth.

What the production landscape looks like today

Algeria today hosts a substantial network of pharmaceutical production sites, ranging from established national groups to subsidiaries of multinationals, and a growing tier of specialized subcontractors.

This density brings two important effects: stronger competition between manufacturers, and a more visible need for differentiation through quality, range, and operational excellence.

• A solid base of generics producers covering essential therapeutic classes
• A growing segment of producers entering biosimilars and specialty products
• Multinationals expanding local partnerships and manufacturing agreements
• A maturing subcontracting ecosystem for packaging, analysis, and logistics
• Increasing focus on production lines aligned with international standards

Operational shifts inside manufacturing sites

Inside the sites, the day-to-day reality is changing. Quality systems are tightening, deviations are tracked more rigorously, and qualification protocols have become a structural part of operations rather than an occasional exercise.

Production leaders are expected to think beyond throughput. They must integrate compliance, traceability, and continuous improvement into their daily decision-making.

What it changes for hiring

As production sites become more demanding, the talent gap widens. Hiring is no longer about filling a line role — it is about finding profiles who can sustain a quality-driven environment.

• Production managers with documented GMP experience
• Maintenance and engineering profiles familiar with qualified equipment
• QC analysts able to operate in modern laboratories
• QA officers capable of supporting daily production decisions
• Supply chain leads experienced in regulated, traceable flows

Key takeaway

Algeria’s local pharmaceutical production has moved into a more demanding phase. The companies that build robust, skilled teams will define the next chapter of the industry — and the hiring choices they make in 2026 will shape what their sites look like for years to come.